Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Mol Cancer Ther. 2010 Sep 3;9(11):3065–3073. doi: 10.1158/1535-7163.MCT-10-0623

Figure 7. Pharmaceutical profiling of Bcr-Abl inhibition by TKIs.

Figure 7

Two examples of the potential utility of Picchu FRET in pharmaceutical profiling of clinically relevant Bcr-Abl mutations as to their efficient inhibition by therapeutics of varying concentrations. Inhibition is depicted as a function of TKI concentration (left), time (bottom) and ΔFRET ratios (right) for Imatinib (top) and Dasatinib (bottom) to provide a pharmaceutical signature for Bcr-Abl proteins. These data can be extrapolated to select the optimum therapeutic, or combination thereof, for different Bcr-Abl mutations for the selection of TKIs with the most desirable kinase inhibition profiles.